SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

The iShares Silver Trust is experiencing a parabolic surge, fueled by escalating industrial demand for silver in new technologies and anticipation of China's upcoming export restrictions. Community discussion highlights a potential short squeeze and belief that long-term price suppression is ending, though some anticipate a sharp correction after such an aggressive run.

SPDR Gold Trust - SPDR Gold Shares

SPDR Gold Shares ETF

GLD is trending with gold prices reaching new all-time highs, driven by escalating geopolitical tensions, a weakening dollar, and widespread anticipation of significant Fed monetary easing. The community is actively debating whether this surge reflects a "currency reset" and a flight to real assets amid an over-indebted global environment, or if it signals an overheated market due for a correction, with many noting a rotation of investment capital from cryptocurrencies into precious metals.

🔥 COCK Token – The Ultimate Cross-Chain MemeFi Powerhouse 🔥  In just under 20 days, $COCK has smashed expectations, broken ATHs, and built a project that’s shaking up Cardano and the entire crypto space. 🐓 What Makes $COCK Special?      The Name: Love it or hate it, the energy and engagement it generates are undeniable. The nuance in language and wild appeal set us apart.     #MEMEFI Pioneer: We’re not just another meme coin. $COCK is leading a movement by combining DeFi mechanics, game theory, and community engagement into a groundbreaking ecosystem.     COCKARENA: At the core of our ecosystem is the COCKARENA, a PvP HODL game. Players battle it out, and early exit fees fuel redistributions, burns, and the treasury. This ensures price appreciation and long-term sustainability for loyal holders.  🎰 The COCK Casino  Our casino isn’t just fun—it’s a serious revenue stream for the FLOCK.      Games: Bonanza, Crash, Blackjack, and Roulette (coming soon!).     Impact: Over 7,834 ADA in profits generated within days, directly supporting rewards, burns, and reinvestment.  💰 COCK-ARENA Loans  Unlock liquidity without selling your tokens.      Loan Terms: Borrow up to 30% of your holdings while continuing to earn rewards in the arena.     Investor Focus: Perfect for savvy investors staying in the game while tapping into their holdings.  🤝 Our Insane Partnerships  We’re bridging gaps, building alliances, and breaking barriers across the crypto space. Key Partners:      DANZO: Powering #MEMEFI with Arena, Casino, and Loans.     KLENEK: Interactive training room.     HSKN (Charles Hoskilien): Supporting and starting COCKPIN with 115 AIR NODES for DePIN aggregation. Plans to add APEX and Earth Nodes through a crypto company incorporated in Costa Rica.     ELITE CATS / SNEKKIES / HOT / BANK: Rewarding NFT holders with COCK-LOCK tokens and vice versa.     OCKZ: COCKSOCKS, Golden Cock Ticket (1M COCK), airdrop rewards, and whitelist perks for holders of 200 ADA worth of $COCK.     OLI Partnership:         Content Creation: Lux and the team are crafting engaging educational content about memes and MemeFi for OLi's platform.         Strategic Investment: The OLi Community Trust will invest in $COCK, distributing 100% of rewards to $OLI holders.         Community Reach: Over 22,000 learners will discover $COCK through OLi's gamified ecosystem.     Hi-Rez the Rapper: Expanding reach in marketing and entertainment.     KUNO, CALEB, CADEN, FITY, ROVER, WhaleInsider: Influential collaborators driving crypto adoption and growth.     Cardano Girls: Helping us understand and communicate effectively with ADA’s female audience.     WallStreetBets: Breaking barriers and increasing engagement.     Antonio Brown: Endorsing, supporting, and even playing in the casino and arena!     Advisors:         BERIS, HECKTHESNEK, RTB, CRYPTOGENIUS: Trusted names advising and supporting the project.  Future Partnerships:  More collaborations are in the pipeline to continue expanding engagement and bring new eyes to ADA and CNTs. 🔥 Unmatched Results in Just 20 Days      Supply Burned: 1.65%, worth 148K ADA!     Arena Fees Collected: 54M COCK, worth over 500K ADA, fueling rewards, burns, and partnerships.     Staked COCK-LOCK: 11M COCK-LOCK in the liquid staking platform, with more coming.     Casino Revenue: Skyrocketing profits directly rewarding holders and growing the treasury.     Top Blast Contests: Generated over 120K ADA in volume, rewarding participants with over 50K ADA in prizes.  🌍 Our Vision  To be the most decentralized, rewarding, and innovative token on Cardano while fostering cross-chain collaboration and onboarding the masses.      Breaking Barriers: We’re bringing BTC, ETH, SOL, and other chains into the fold.     Community-Driven: Focused on building bridges and showcasing that crypto can be fun, rewarding, and sustainable.     Expansion: This is just the beginning. With more burns, rewards, and partnerships on the way, $COCK is set to redefine what’s possible in the MemeFi space.  💎 Time in the arena > Timing the market. The FLOCK is unstoppable. Let’s keep breaking walls for Cardano and onboard new users as we take $COCK to new heights.

CockCardano

COCK CRYPTO is trending due to its real-world asset integration via Cocky Wings LLC, which is actively generating revenue and performing token buybacks, enhancing liquidity. The community on Cardano is highly engaged, discussing its new DApp, passive earning opportunities in the 'Arena,' and its long-term potential as a utility-backed meme coin.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is generating considerable excitement, propelled by its AI-powered Athena platform and recent Marigold acquisition, with upcoming events like CES fueling significant anticipation. The community increasingly recognizes ZETA as an undervalued AI marketing technology leader, positioned for a substantial re-rating as institutional interest grows and analysts project robust future expansion. Many believe its unique first-party data advantage sets the stage for a powerful breakout.

Sprott Physical Silver Trust - Units

Sprott Physical Silver Trust ET

Sprott Physical Silver Trust (PSLV) is experiencing significant attention as the community widely discusses a powerful silver squeeze, driven by a growing structural supply deficit and surging industrial demand across critical sectors. Many believe long-standing market suppression is breaking, potentially leading to a historic price discovery phase. Investor conversations emphasize the intrinsic value of physical silver as a hedge against broader economic uncertainties.

Dog (Bitcoin) is a fully decentralized memecoin on the Bitcoin blockchain, backed by a community dedicated to onboarding millions of people to Bitcoin.  Dog is secured by the Bitcoin blockchain and exists on Bitcoin L1, marking a significant innovation compared to Bitcoin with just BTC. Dog is a Bitcoin Runes token with a minimal on-chain footprint, native to Bitcoin, and stored in UTXOs, just like Bitcoin.   What is the project about?  Dog does not do any paid promotion and is fully decentralized just like Bitcoin. Every influencer who chooses to post about Dog either received the airdrop or bought on secondary. Dog leverages the CC0 license to ensure that Dog is not owned by any single entity but rather by everyone. This had lead to the "DOG Army" independently creating art, apps, lotteries, plushies, websites, podcast, magazines, X account, IRL meetups, clothing lines, PFP collections, Telegram groups, and TikTok/Instagram about Dog.  What makes your project unique?  Dog was airdropped in the fairest memecoin launch ever. In early 2024, the Bitcoin Ordinals ecosystem came together in a full volunteer initiative that rewarded early adopters of the Ordinals Protocol. There was no team allocation, and 100% of the supply was airdropped for free. The airdrop algorithm favored neither whales nor influencers; it was determined by the community and made open-source for maximum transparency.

Dog (Bitcoin)

DOG CRYPTO is trending due to significant community discussion around its unique position as a Bitcoin-native memecoin, particularly on the Runes protocol. Bulls are highlighting recent strategic acquisitions by C2 Blockchain, which has notably expanded its $DOG treasury. The "DOG Army" expresses strong conviction, positioning $DOG as a contender to "drop the E" and become a dominant meme asset on the secure Bitcoin network.

ProShares Trust - ProShares Ultra Silver 2x Shares

ProShares Trust - ProShares Ultra Silver

ProShares Ultra Silver (AGQ) is currently trending amidst widespread community belief in a historic silver breakout, driven by strong industrial demand, geopolitical instability, and anticipation of central bank dovish pivots. Investors are actively discussing extreme upside targets for silver and its leveraged ETFs, with many highlighting its undervalued status relative to gold and expressing a "silver squeeze" narrative.

A SPAC III Acquisition Corp. is a blank check company. The company was created for the purpose of effecting a merger, asset acquisition, share purchase, reorganization or similar business combination. The company was founded on September 3, 2021 and is headquartered in Hong Kong.

A SPAC III Acquisition Corp. - Ordinary Shares - Class A

Alpha Capital Acquisition Co - Ordinary Shares - Class A

ASPC is experiencing extreme price volatility and massive trading volume, sparking widespread community discussion around a potential short squeeze. Traders are actively debating its rapid movements, with some anticipating significant further momentum while others caution about the inherent risks of such speculative, low-float plays. The overall sentiment is sharply divided between those betting on continued upside and those warning of a pump-and-dump dynamic.

Universe Pharmaceuticals, Inc. is a pharmaceutical company. The firm is focused on the manufacturing, marketing, sales, and distribution of traditional Chinese medicine derivative products. It also sells biomedical drugs, medical instruments, traditional Chinese medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. The company was founded on March 2, 1998 and is headquartered in Ji'an, China.

Universe Pharmaceuticals INC

Universe Pharmaceuticals (UPC) is trending due to a massive surge in trading volume and significant price volatility, driven by its extremely low public float. Community sentiment is highly polarized, with some anticipating a substantial short squeeze and advocating for holding shares for significant gains, while others caution it's a 'pump and dump' given its status as a China-based micro-cap. Discussion often highlights the company's strong cash position relative to its market capitalization, fueling speculation of high intrinsic value and potential for rapid upward movement if buying pressure continues.

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros is trending following the landmark FDA approval of YARTEMLEA, establishing it as the first and only approved therapy for transplant-associated thrombotic microangiopathy (TA-TMA) in both adult and pediatric patients. This pivotal de-risking event, coupled with its strengthened financial position from a major partnership, has fueled community excitement regarding commercialization potential, anticipated analyst upgrades, and significant upside ahead of its upcoming conference call.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Corbus Pharmaceuticals (NASDAQ:CRBP) Shares Cross Below Fifty Day Moving Average - Should You Sell?

Corbus Pharmaceuticals (NASDAQ:CRBP) Share Price Passes Below Fifty Day Moving Average - Here's What Happened...

<ul class="summary-bullets"><li>CRB-913 is an oral small-molecule inverse agonist targeting the CB1 receptor, a known pathway for weight loss.</li><li>The study showed that participants reported reductions in food-related thoughts and cravings</li><li>Corbus has initiated a Phase 1b dose-finding study, CANYON-1, in people with obesity, with completion expected by summer 2026.</li></ul>Shares of Corbus Pharmaceuticals Holdings, Inc. (CRBP) surged 36% in premarket trading on Thursday after the company announced encouraging Phase 1a results for CRB-913, an oral CB1 inverse agonist targeting chronic obesity.At the time of writing, <a href="https://stocktwits.com/symbol/CRBP">CRBP</a> was among the top trending tickers on Stocktwits.<h2 class="st-heading-2">Results Of The Study</h2>Corbus Pharma said that the single-and multiple-ascending dose study showed that CRB-913 was safe and well-tolerated across all doses, with no serious treatment-emergent adverse events reported. Gastrointestinal issues were minimal, and daily neuropsychiatric assessments remained negative, indicating no signs of suicidality, depression, or anxiety.Participants reported reductions in food-related thoughts and cravings, highlighting early behavioral effects alongside weight reduction. Pharmacokinetic analysis confirmed that CRB-913 is suitable for once-daily oral dosing.Building on the early results, Corbus has initiated a Phase 1b dose-finding study, CANYON-1, in people with obesity, with completion expected by summer 2026. This next stage will further explore optimal dosing and continue evaluating safety, tolerability, and efficacy over a longer period.CRB-913 is an oral small-molecule inverse agonist targeting the CB1 receptor, a known pathway for weight loss. Unlike earlier drugs in this class that raised neuropsychiatric safety concerns, CRB-913 is designed for limited brain penetration to reduce those risks.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Retail sentiment flipped to ‘extremely’ bullish from ‘neutral’ a day earlier, accompanied by ‘extremely high’ message volumes.One user expressed optimism about the CANYON-1 study.<stembedurl>https://stocktwits.com/LuigiDurante/message/638840548</stembedurl>Year-to-date, the stock has declined nearly 15%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/msft-stock-appears-set-to-retest-200-dma-last-time-it-did-its-rebound-didn-t-endure/cLIxBZBREnI">MSFT Stock Appears Set To Retest 200-DMA – Last Time It Did, Its Rebound Didn’t Endure</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

CRBP Stock Surged 36% Pre-Market – What Did Its Obesity Treatment Drug Study Reveal?

Corbus Pharmaceuticals said its Phase 1a study showed CRB-913 was safe and well-tolerated at all doses, with no serious adverse events reported.

Equity

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Receives Consensus Rating of "Moderate Buy" from Analysts

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eleven ratings firms that are covering the stock, Marketbeat...

B. Riley Forecasts Lower Earnings for Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Equities researchers at B. Riley dropped their FY2025 earnings per share estimates for Corbus Pharmaceuticals in a report released...

What is B. Riley's Forecast for CRBP FY2029 Earnings?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Research analysts at B. Riley issued their FY2029 EPS estimates for Corbus Pharmaceuticals in a research note issued to investors...

Research Analysts Issue Forecasts for CRBP Q1 Earnings

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Free Report) - Analysts at HC Wainwright issued their Q1 2026 earnings estimates for Corbus Pharmaceuticals in a research note issued to investors...

Royal Bank Of Canada Lowers Corbus Pharmaceuticals (NASDAQ:CRBP) Price Target to $53.00

Royal Bank Of Canada reduced their target price on shares of Corbus Pharmaceuticals from $55.00 to $53.00 and set an "outperform" rating on the stock in a research report on Thursday...

Corbus Pharmaceuticals (NASDAQ:CRBP) Announces Earnings Results, Misses Expectations By $0.10 EPS

Corbus Pharmaceuticals (NASDAQ:CRBP - Get Free Report) announced its quarterly earnings results on Wednesday. The biopharmaceutical company reported ($1.90) EPS for the quarter, missing the consensus...

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Given Average Rating of "Moderate Buy" by Brokerages

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP - Get Free Report) has earned an average rating of "Moderate Buy" from the eleven brokerages that are covering the stock, MarketBeat Ratings...

Can Cannabis Stocks Reverse Their Prolonged Downtrend?

Cannabis stocks like TLRY and GTBIF remain deep in years-long slump, but U.S. federal reform or global expansion could ignite a long-awaited rebound.

Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.

CRBP
Corbus Pharmaceuticals Holdings Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CRBP News

CRBPCorbus Pharmaceuticals Holdings Inc